NCT06261164

Population Pharmacokinetic Model of Amikacin and Vancomycin in Critically Ill Patients

Name: Clinical Trial NCT06261164
Creator: University Clinical Centre of Republic of Srpska
Keywords: Sepsis, Cytosorb® and Oxiris® adsorbents, device, clinical trial, Bosnia and Herzegovina

Development and Use of a Population Pharmacokinetic Model of Amikacin and Vancomycin for the Optimization of Dosing Regimens in Critically Ill Patients on Different Modalities of Extracorporeal Hemoadsorption

University Clinical Centre of Republic of Srpska·ClinicalTrials.gov·device·Device trialRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Sepsis
Drug/Device/Intervention: Cytosorb® and Oxiris® adsorbents
Study type: Observational
Intervention type: device

Sponsor & location

Primary sponsor: University Clinical Centre of Republic of Srpska
Location: Banja Luka, Bosnia and Herzegovina

Timeline & enrollment

Phase: N/A
Start date: Jan 31, 2024
End date: Jan 31, 2025
Enrollment: 20 participants

Primary outcome

Development of population pharmacokinetic model

Summary

The object of the scientific research is the characterization of the pharmacokinetic profile and the investigation of factors of pharmacokinetic variability of amikacin and vacnomycin in critically ill patients with a diagnosis of sepsis-like condition (SIRS), hospital-acquired sepsis and/or septic shock and who are on extracorporeal therapy with Cytosorb® and Oxiris® adsorbents.

ICD-10 classifications

Other sepsisSepsis, unspecifiedOther specified sepsisCandidal sepsisPuerperal sepsis

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06261164
Type: Device Trial

About this record

Access comprehensive clinical trial information for NCT06261164 through Pure Global AI's free database. This phase not specified trial is sponsored by University Clinical Centre of Republic of Srpska and is currently Recruiting. The study focuses on Sepsis. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.